New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT06967103
Summary
This study is testing whether adding an experimental drug called QL1706 to standard chemotherapy works better than chemotherapy alone when given before surgery for a common type of breast cancer (HR+/HER2-). It will involve 238 women to see if the combination helps eliminate all detectable cancer in the breast and lymph nodes by the time of surgery. The trial will also closely monitor side effects to understand the safety of this new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.